A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis.

Ida Vittrup Niels Steen KroghHenrik Hedegaard Pliess LarsenJesper Elbeling Lone Skov Kristina Sophie Ibler Gregor Borut Ernst Jemec Charlotte Gotthard Mortz Rasmus Overgaard Bach Carsten Bindslev-JensenMaiken Glud DalagerAlexander Egeberg Tove Agner Mette Deleuran Christian Vestergaard Jacob Pontoppidan Thyssen

Published in: Journal of the European Academy of Dermatology and Venereology : JEADV (2023)

While 2-year drug survival was 86%, dupilumab was unable to effectively treat AD in the head-and-neck area, and conjunctivitis was found in 25% of patients.

Keyphrases

atopic dermatitis
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
cross sectional
drug induced
adverse drug
preterm birth